bioMérieux S.A.

LSE:0RUG Stock Report

Market Cap: €12.1b

bioMérieux Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Pierre Boulud

Chief executive officer

€2.5m

Total compensation

CEO salary percentage25.7%
CEO tenure1.4yrs
CEO ownershipn/a
Management average tenure3.4yrs
Board average tenure10.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Pierre Boulud's remuneration changed compared to bioMérieux's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

€411m

Mar 31 2024n/an/a

€384m

Dec 31 2023€2m€631k

€358m

Sep 30 2023n/an/a

€372m

Jun 30 2023n/an/a

€386m

Mar 31 2023n/an/a

€419m

Dec 31 2022€2m€510k

€452m

Sep 30 2022n/an/a

€502m

Jun 30 2022n/an/a

€552m

Mar 31 2022n/an/a

€577m

Dec 31 2021€2m€510k

€601m

Sep 30 2021n/an/a

€555m

Jun 30 2021n/an/a

€509m

Mar 31 2021n/an/a

€457m

Dec 31 2020€1m€497k

€404m

Compensation vs Market: Pierre's total compensation ($USD2.56M) is below average for companies of similar size in the UK market ($USD5.77M).

Compensation vs Earnings: Pierre's compensation has increased by more than 20% in the past year.

CEO

Pierre Boulud (53 yo)

1.4yrs

Tenure

€2,452,864

Compensation

Mr. Pierre Boulud is Chief Executive Officer of bioMérieux S.A. from July 01, 2023. He served as Chief Operating Officer of Clinical Operations at BioMérieux S.A. until 2023 and served as its Chief Operati...

Leadership Team

NamePositionTenureCompensationOwnership
Pierre Boulud
Chief Executive Officer1.4yrs€2.45mno data
Guillaume Bouhours
Executive VP of Purchasing and Information Systems & CFO6.8yrsno datano data
Sylvain Morgeau
Investor Relationsno datano datano data
Audrey Dauvet
Executive Vice President of Legal1.9yrsno datano data
Valerie Leylde
Executive Vice President of Human Resources5.9yrsno datano data
Pierre Charbonnier
Executive Vice President of Global Quality6.8yrsno datano data
Yasha Mitrotti
Executive Vice President of Industrial Applications6.8yrsno datano data
Frederic Beseme
Head of CSR4.9yrs€21.99kno data
Jennifer Zinn
Executive Vice President of Clinical Operations1.3yrsno datano data
Charles Cooper
Executive VP & Chief Medical Officerless than a yearno datano data
Celine Roger-Dalbert
Executive Vice President of Research & Developmentless than a yearno datano data
Franck Admant
Director of Investor Relationsno datano datano data

3.4yrs

Average Tenure

51.5yo

Average Age

Experienced Management: 0RUG's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alain Merieux
Founding Chairman7.3yrsno datano data
Jean-Luc Belingard
Non-Independent Director18.3yrs€52.00k0.051%
€ 6.1m
Philippe Archinard
Non-Independent Director14.5yrs€61.00k0.000030%
€ 3.6k
Alexandre Merieux
Chairman20.7yrs€1.92m0.000050%
€ 6.0k
Harold Y. Boel
Independent Director12.6yrs€56.00k0.00013%
€ 15.7k
Marie-Helene Habert-Dassault
Independent Director12.6yrs€44.00k0.000050%
€ 6.0k
Fanny Letier
Independent Director7.6yrs€61.17k0.000030%
€ 3.6k
Viviane Monges
Independent Directorless than a yearno datano data
Marie-Paule Kieny
Independent Director7.3yrs€35.00k0.00015%
€ 18.1k
Sylvain Orenga
Employee Representative Director2.6yrs€52.00kno data

10.1yrs

Average Tenure

60.5yo

Average Age

Experienced Board: 0RUG's board of directors are seasoned and experienced ( 10.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 04:23
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

bioMérieux S.A. is covered by 34 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Armelle MoulinAlphaValue
Gaurav JainBarclays
Samuel EnglandBerenberg